《原发性肝癌诊疗规范（2019年版）》解读

王姗; 吴庆旺; 李小科; 叶永安

doi:10.3969/j.issn.1001-5256.2020.05.009

《原发性肝癌诊疗规范（2019年版）》解读

DOI: 10.3969/j.issn.1001-5256.2020.05.009

1. 北京中医药大学东直门医院消化科
2. 北京中医药大学东直门医院急诊科

基金项目:

国家科技重大专项“十三五”课题（2018ZX10725-505-001）；

详细信息

中图分类号: R735.7
计量
- 文章访问数: 772
- HTML全文浏览量: 103
- PDF下载量: 716
- 被引次数: 0
出版历程
- 出版日期: 2020-05-20

Interpretation of Guidelines for diagnosis and treatment of primary liver cancer in China (2019edition)

Department of Gastroenterology, Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing 100700, China

Research funding:

摘要

摘要:
2017年6月国家卫生和计划生育委员会发布了《原发性肝癌诊疗规范(2017年版)》,该规范在肝癌的诊断、分期及治疗方面提出推荐性意见,具有重要意义。此后,国内外在原发性肝癌研究方面不断出现符合循证医学原则的高级别证据,为此,国家卫生健康委员会修订更新颁布《原发性肝癌诊疗规范(2019年版)》。对新版规范的更新要点进行解读,以期更好指导临床。
- 肝肿瘤 /
- 诊断 /
- 治疗学 /
- 诊疗准则(主题)
Abstract:
In June 2017, the National Health and Family Planning Commission of the People's Republic of China issued the Guidelines for diagnosis and treatment of primary liver cancer in China(2017 edition), which is of great significance as it provides recommendations on the diagnosis, staging, and treatment of liver cancer. Since then, more and more high-level evidence in accordance with the principles of evidence-based medicine has appeared in research on primary liver cancer around the world, so the National Health Commission of the People's Republic of China revised the 2017 edition of the Guidelines and issued the Guidelines for diagnosis and treatment of primary liver cancer in China(2019 edition). This article interprets the updated key points of the new edition of the Guidelines to better guide clinical treatment.
- liver neoplasms /
- diagnosis /
- therapeutics /
- practice guidelines as topic

HTML全文

参考文献(25)

[1] LI Y, DENG X, WEN B. Research progress of Chinese and Western Medicine on primary liver cancer[J]. Hunan J Tradit Chin Med, 2019, 35(12):134-136.(in Chinese）李亚，邓鑫，文彬．原发性肝癌的中西医研究进展[J]．湖南中医杂志，2019, 35(12):134-136.

[2] National Health and Family Planning Commission of the People’s Republic of China. Diagnosis,management,and treatment of hepatocellular carcinoma(V2017)[J]. J Clin Hepatol,2017, 33(8):1419-1431.(in Chinese）中华人民共和国国家卫生和计划生育委员会．原发性肝癌诊疗规范（2017年版）[J]．临床肝胆病杂志，2017, 33(8):1419-1431.

[3] Bureau of Medical Administration, National Health Commission of the People’ s Republic of China. Guidelines for diagnosis and treatment of primary liver cancer in China(2019 edition)[J]. J Clin Hepatol, 2020, 36(2):277-292.(in Chinese）中华人民共和国国家卫生健康委员会医政医管局．原发性肝癌诊疗规范（2019年版）[J]．临床肝胆病杂志，2020, 36(2):277-292.

[4] Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B(version 2019)[J]. J Clin Hepatol, 2019, 35(12):2648-2669.(in Chinese）中华医学会感染病学分会，中华医学会肝病学分会．慢性乙型肝炎防治指南（2019年版）[J]．临床肝胆病杂志，2019, 35(12):2648-2669.

[5] Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. The guideline of prevention and treatment for hepatitis C:A 2015 update[J]. J Clin Hepatol, 2015, 31(12):1961-1979.(in Chinese）中华医学会肝病学分会，中华医学会感染病学分会．丙型肝炎防治指南（2015年更新版）[J]．临床肝胆病杂志，2015, 31(12):1961-1979.

[6] WANG MQ, FU H, FENG J. Progress in antiviral treatment of hepatitis B-related liver cancer[J/CD]. Electronic J Clin Med Literature, 2020, 7(2):193, 198.(in Chinese）王明芹，付华，冯基．乙肝相关性肝癌抗病毒治疗研究进展[J/CD]．临床医药文献电子杂志，2020, 7(2):193, 198.

[7] RENZULLI M, BISELLI M, BROCCHI S, et al. New hallmark of hepatocellular carcinoma, early hepatocellular carcinoma and high-grade dysplastic nodules on Gd-EOB-DTPA MRI in patients with cirrhosis:A new diagnostic algorithm[J]. Gut,2018, 67(9):1674-1682.

[8] INCHINGOLO R, FALETTI R, GRAZIOLI L, et al. MR with Gd-EOB-DTPA in assessment of liver nodules in cirrhotic patients[J]. World J Hepatol, 2018, 10(7):462-473.

[9] FRAUM TJ, FOWLER KJ, MCCONATHY J. PET/MRI:Emerging clinical applications in oncology[J]. Acad Radiol, 2016,23(2):220-236.

[10] EHMAN EC, JOHNSON GB, VILLANUEVA-MEYER JE, et al.PET/MRI:Where might it replace PET/CT?[J]. J Magn Reson Imaging, 2017, 46(5):1247-1262.

[11] SUN GB, PENG L, MA B, et al. Clinical experience of radiofrequency treatment of 80 cases of liver cancer[J]. Clin J Med Offic, 2019, 47(9):987-988.(in Chinese）孙高斌，彭玲，马波，等．肝癌射频治疗80例临床经验总结[J]．临床军医杂志，2019, 47(9):987-988.

[12] PENG ZW, LIN XJ, ZHANG YJ, et al. Radiofrequency ablation versus hepatic resection for the treatment of hepatocellular carcinomas 2 cm or smaller:A retrospective comparative study[J]. Radiology, 2012, 262(3):1022-1033.

[13] KIM YS, LIM HK, RHIM H, et al. Ten-year outcomes of percutaneous radiofrequency ablation as first-line therapy of early hepatocellular carcinoma:Analysis of prognostic factors[J]. J Hepatol, 2013, 58(1):89-97.

[14] YUAN GQ, MO CJ, ZHANG ZC. Clinical effect of transarterial chemoembolization combined with radiofrequency ablation in the treatment of primary liver cancer[J]. Clin J Med Offic,2019, 47(10):1126-1127.(in Chinese）袁广庆，莫灿均，张志成．肝动脉化疗栓塞联合射频消融治疗原发性肝癌临床疗效观察[J]．临床军医杂志，2019, 47(10):1126-1127.

[15] The Chinese Society of Nuclear Medicine Working Committee for Treatment of Bone Metastasis. Expert consensus on strontium-89 chloride treatment of bone metastases(2017)[J].Chin J Nucl Med Mol Imaging, 2018, 38(6):412-415.(in Chinese）中华医学会核医学分会转移性骨肿瘤治疗工作委员会．氯化锶[89Sr]治疗转移性骨肿瘤专家共识（2017年版）[J]．中华核医学与分子影像杂志，2018, 38(6):412-415.

[16] XIONG Y. Development of TCM theory and clinical research on primary liver cancer[D]. Chongqing:Chongqing Medical University, 2019.(in Chinese）熊雨．原发性肝癌中医理论及临床研究进展[D]．重庆：重庆医科大学，2019.

[17] DANG L, CHAO X. Clinical research progress of acupuncture and moxibustion in the treatment of primary liver cancer[J].Global Tradit Chin Med, 2018, 11(9):1488-1491.(in Chinese）党琳，晁旭．针灸治疗原发性肝癌的临床研究进展[J]．环球中医药，2018, 11(9):1488-1491.

[18] LIN Q, LI MJ, LI HQ, et al. A survey of the study on external treatment of liver cancer in traditional Chinese Medicine[J].Hunan J Tradit Chin Med, 2016, 32(5):188-190.(in Chinese）林青，李民杰，李海强，等．肝癌的中医外治法研究概况[J]．湖南中医杂志，2016, 32(5):188-190.

[19] ROCKEY DC, CALDWELL SH, GOODMAN ZD, et al. Liver biopsy[J]. Hepatology, 2009, 49(3):1017-1044.

[20] QU KZ, ZHANG K, LI H, et al. Circulating microRNAs as biomarkers for hepatocellular carcinoma[J]. J Clin Gastroenterol, 2011, 45(4):355-360.

[21] LI G, SHEN Q, LI C, et al. Identification of circulating microRNAs as novel potential biomarkers for hepatocellular carcinoma detection:A systematic review and meta-analysis[J]. Clin Transl Oncol, 2015, 17(9):684-693.

[22] ZHOU J, YU L, GAO X, et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma[J]. J Clin Oncol, 2011, 29(36):4781-4788.

[23] WANG B. Detection of clonal origin and clinical significance of multinodular and recurrent HCC by microsatellite loss of heterozygosity[D]. Shanghai:Second Military Medical University, 2009.(in Chinese）王斌．微卫星杂合性缺失检测多结节性和复发性肝细胞癌克隆起源及其临床意义[D]．上海：第二军医大学，2009.

[24] CONG WM. Current situation and consideration of clinicopathological study of multinodular liver cancer[C]. Data collection of the 15th National Academic Conference on liver cancer.Zhengzhou, 2015.(in Chinese）丛文铭．多结节性肝癌临床病理学研究的现状与思考[C]．第十五届全国肝癌学术会议资料汇编．郑州，2015.

[25] WANG B, XIA CY, LAU WY, et al. Determination of clonal origin of recurrent hepatocellular carcinoma for personalized therapy and outcomes evaluation:A new strategy for hepatic surgery[J]. J Am Coll Surg, 2013, 217(6):1054-1062.

施引文献

资源附件(0)

访问统计